Mechanisms, Management, and Treatment of Fibrosis in Patients With Inflammatory Bowel Diseases.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 27720839.
- Also identified by DOI 10.1053/j.gastro.2016.09.047 and PMC identifier 5209279.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
In the last 10 years, we have learned much about the pathogenesis, diagnosis, and management of intestinal fibrosis in patients with inflammatory bowel diseases. Just a decade ago, intestinal strictures were considered to be an inevitable consequence of long-term inflammation in patients who did not respond to anti-inflammatory therapies. Inflammatory bowel diseases-associated fibrosis was seen as an irreversible process that frequently led to intestinal obstructions requiring surgical intervention. This paradigm has changed rapidly, due to the antifibrotic approaches that may become available. We review the mechanisms and diagnosis of this serious complication of inflammatory bowel diseases, as well as factors that predict its progression and management strategies.
Medical subject headings
- Fibroblasts
- Inflammatory Bowel Diseases
- Intestinal Diseases
- Intestines
- Myofibroblasts